Trastuzumab–MCC-DM1 is a novel agent composed of the cytotoxic DM1 conjugated to trastuzumab, now in Phase II studies for HER2-positive MBC cases. The relative importance and activity of these ...

A further novel approach is the conjugation of cytotoxic agents to targeted agents, such as with trastuzumab-MCC-DM1. Elucidating the relative importance of these agents and incorporating them ...

trastuzumab plus an additional HER2-directed agent); and pathological nodal status after neoadjuvant therapy (node-positive vs. node-negative or not evaluated). Radiation and endocrine therapy ...

An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...

Trastuzumab Emtansine ADC biosimilar is developmental ... Due to this technology the targeted delivery of the cytotoxic agent is enabled and the other toxicities on body are reduced.